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Introduction
The nephroblastoma or Wilms tumor (WT)is the commonest solid childhood renal tumor, accounting for about 6% of all pediatric malignancies [1] . It predominantly affects children less than five years of age, with 90% of new cases diagnosed before age of three years [1, 2] . The cancer treatment in childhood is expensive especially in the Low-income countries with a low and very low GDP per capita. Cost of illness includes three categories: Direct, Indirect, and Psychosocial costs [3] . Typically it involves periods of hospitalization,time spent by physician and other professional services, use of laboratory and other diagnostic tests, administration of chemotherapy, use of other pharmaceuticals and surgical or radiotherapy approach.
All these components impose a large financial burden on health-care systems and on the families of the children who are affected [4] .
Rwanda is a Low-income country, with a GDP per capita which 
Objectives
The objectives of the study were the calculation of the direct cost of treatment of Wilms tumor in Rwanda, the evaluation of feasibility of treatment and identification of the major obstacles of treating this disease.
Methods
It was a hospital based prospective descriptive study of patients with nephroblastoma treated in the pediatric department of Kigali University Teaching Hospital within 2 years period from the 01 January 2010-31 December 2011. The KUTH is located in the Center of Kigali city and is the main public health institution in Rwanda.
During the study period the hospital was the only public referral hospital in the country where childhood cancer was diagnosed and treated. It serves normally one to two million people from a largely urban and rural area, children representing more than 40% of the population.
The patients were followed during the period of this study, and readmitted several times in the Pediatric Oncology Unit Table 1) . For surgical purpose, abdominal ultrasound was repeated for all cases after the preoperative chemotherapy course.
In the following one to two weeks after preoperative chemotherapy, 
Cost calculation
The cost was calculated using 2010-2011 tariffs applied by the hospital. The cost items have been identified and activity reports were used for calculating the total costs using unit prices and occurrences. We consulted the Accounting Department of UTHKigali in order to get the price of every variable concerned. It consisted of costs of hospitalization, chemotherapy drugs and supportive treatment like transfusions and intravenous fluid used, investigations, surgical intervention and transport fees. However the transport fees were not included into calculations in determining the total cost as it differed from patient to patient, but counted as a contributing factor to the treatment adherence. The cost for transport was calculated separately and we consulted the price of common bus transport regulation agency available in 2011.
The total cost presented in this paper did not take in consideration the time spent by the medical staff with each patient or their salaries. The currency used was in Rwandan francs and the costs were converted in United States Dollars (USD) at the exchange rate that was on market at the end of December 2011(1 USD= 605 RFW).
Factors related to treatment compliance
The data were collected on a structured standardized questionnaire The management of patients with Nephroblastoma at Kigali University Teaching Hospital was affected by several factors such as unaffordable treatment due to poverty representing 80% followed by poor compliance to treatment due to lack of transport fees in 72% and late presentation in 56%. More than half of the mothers of the patients (18 out 25) described the lack of financial funds as the main reason for not affording the transport ( Table 2 ). In 6 cases the histopathology report was released with a delay of more than 3 weeks after the operation and 2 patients with advanced diseases were operated later than 2 weeks from the last preoperative chemotherapy due to co morbidities and severe malnutrition. 
Discussion
The Wilms tumor or Nephroblastoma is the commonest childhood cancer in Rwanda. The peak age incidence of 2-5 years and the sex ratio in this study is similar to other international studies [6] . The distribution of the stages in Rwanda reflects the general situation of most patients in numerous African countries that is late and with advanced disease. Late presentation is a common problem in developing countries and may be probably related mostly to ignorance and poverty [7] .
In addition to that, most of these children are usually first managed in a primary care center where facilities and qualified personnel needed for early diagnosis are missing. The Kigali University Teaching Hospital, in the period under review, was the only one referral public Hospital taking care of these children with cancer in the country therefore we received patients from all over the country thus transport was a vital issue adding to the cost as well as the delay in diagnosis; this was similar to the results reported elsewhere [7] . Collaborative efforts among Surgeons, Pathologists, Pediatricians, and Radiologists have been regarded as a major factor in excellent outcome from current management of WT [6, 8] .
The multidisciplinary approach was impaired in the management of WT in the period under review; the delay in surgical intervention and histopathology report was 8% and 24% respectively. The definitive management of WT involves surgery, chemotherapy and radiotherapy for the patients with advanced stage disease. In our study, none of our patients had radiotherapy, as radiotherapy machines are not available in the country. The cost was mostly driven by the high cost of chemotherapy drugs and the lack of money for transport for the patients. A poor compliance of the treatment, following the chemotherapy regimen was described in similar studies in Sudan [7] . Our findings differ from previous studies reported in the literature due to the fact that pathology, radiotherapy, chemotherapy drugs, and in-hospital days in Rwanda are not free services or at a very minimal cost [9] .
Nephroblastoma is regarded as one of the successes of pediatric oncology with long-term survival approaching 90% and 70% for localized and metastatic diseases [6, 10] . Out of 25 patients treated for Wilms tumor at Kigali University Teaching Hospital, five patients (20%) withdrew with the remaining completing the chemotherapy protocol. More than half of them presented with advanced disease.
The overall survival is not known as many patients were lost to follow up. The rate of abandonment in our settings is a reflection of problems peculiar to the least developed and developing countries, problems with fundamental issues such as poverty, ignorance, and high cost of the drugs with inadequate and inefficient supply.
Conclusion
The results from our study present the real costs of the most AMD -Actinomycin; VCR -Vincristine; DOX -Doxorubicin 
